Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.

Siddharth Mittal, MD and CEO of Biocon said the company will launch Liraglutide in Europe in FY26 along with its partner, ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...